US 12,239,677 B2
Therapeutic bacteriophage compositions for treating Staphylococcus infection
Sandra P. Morales, Sydney (AU); Gillian Mearns, Sydney (AU); Deborah A. Rankin, Sydney (AU); and Frenk Smrekar, Ljubjlana (SI)
Assigned to ARMATA PHARMACEUTICALS, INC., Marina del Rey, CA (US)
Filed by ARMATA PHARMACEUTICALS, INC., Marina del Rey, CA (US)
Filed on Apr. 14, 2023, as Appl. No. 18/301,188.
Application 18/301,188 is a division of application No. 16/959,666, granted, now 11,654,166, previously published as PCT/US2019/012114, filed on Jan. 2, 2019.
Claims priority of provisional application 62/731,775, filed on Sep. 14, 2018.
Claims priority of provisional application 62/678,611, filed on May 31, 2018.
Claims priority of provisional application 62/613,050, filed on Jan. 2, 2018.
Prior Publication US 2023/0248789 A1, Aug. 10, 2023
Int. Cl. A61K 35/76 (2015.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 31/43 (2006.01); A61K 31/47 (2006.01); A61K 31/545 (2006.01); A61K 31/65 (2006.01); A61K 45/06 (2006.01); A61P 31/04 (2006.01); A61P 31/14 (2006.01)
CPC A61K 35/76 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/43 (2013.01); A61K 31/545 (2013.01); A61K 31/65 (2013.01); A61P 31/04 (2018.01); A61P 31/14 (2018.01); A61K 31/47 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01)] 28 Claims
 
1. A method of treating a human with a bacterial infection comprising administration to said human a composition comprising one or more distinct bacteriophages that infect and lyse Staphylococcus aureus and having a genome comprising a polynucleotide sequence having at least 95% identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; wherein the bacterial infection is caused by Staphylococcus aureus.